Program
pociredir
Also written as “Pociredir”, “Pociredir oral capsule(s)” and “FTX-6058 - Two Dosing Periods”.
Its studies are mostly in Anemia, Sickle Cell, led by Fulcrum Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fulcrum Therapeutics | 40 open or running | phase 2since Jan 28, 2026 | Oct 5, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 5, 2020First study: phase 1 study in Anemia, Sickle CellFirst studyNCT04586985 · 109 enrolled · United States
- Dec 14, 2021Phase 1 study in Anemia, Sickle CellNCT05169580 · 45 enrolled · United States, Nigeria, South Africa
- Jan 28, 2026Phase 2 study in Anemia, Sickle CellPhase 2 reachedNCT07401823 · 1 enrolled · United States
- Feb 18, 2026Phase 1 study in Anemia, Sickle CellNCT07431398 · 13 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07431398Anemia, Sickle Cell · United States | 1 | Terminated | Jun 1, 2026 | 13 |
| NCT07401823Anemia, Sickle Cell · United States | 2 | Terminated | Jun 4, 2026 | 1 |
| NCT05169580Anemia, Sickle Cell · United States, Nigeria, South Africa | 1 | Completed | Jan 20, 2026 | 45 |
| NCT04586985Anemia, Sickle Cell · United States | 1 | Completed | Nov 15, 2022 | 109 |
How it is read
Names in the registry
- “Pociredir”, 2 entries
- “Pociredir oral capsule(s)”, 1 entry
- “FTX-6058 - Two Dosing Periods”, 1 entry
- “FTX-6058 / Midazolam Syrup”, 1 entry
Codes read as this program: FTX6058.
Conditions, from the studies’ own filings
- Anemia, Sickle Cell, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.